Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer

Arends, T.J.H.; Nativ, Ofer; Maffezzini, Massimo; Cobelli, Ottavio De; Canepa, G; Verweij, Fabrizio; Moskovitz, Boaz; Heijden, Antoine G. van der; Witjes, J. Alfred

doi:10.1016/j.eururo.2016.01.006

Cited by 204 publications

(131 citation statements)

References 16 publications

Supporting

Mentioning

119

Contrasting

Unclassified

Order By: Relevance

“…However, 58 the exact surveillance protocol and treatment regime vary between 59 countries according to which of the published guidelines are fol- 60 lowed. In this report, we compare five guidelines: from Europe, 61 (European Association of Urology, EAU-2015) [3], the United States 62 (National Comprehensive Cancer Network, NCCN-2015) [6], the 63 United Kingdom (National Institute for Health and Care Excellence, 64 NICE-2015) [7], Japan (Japanese Urological Association, JUA-2010) 65 [8] and the International Consultation on Bladder Cancer, 2012 [9]. We review these recommendations for diagnosis, TUR, 67 intravesical treatment and surveillance protocols for this disease 68 and discuss the evidence for these recommendations.…”

mentioning

confidence: 99%

Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia

Tan

Rodney

Lamb

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

mentioning

confidence: 99%

Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia

Tan

Rodney

Lamb

et al. 2016

Cancer Treatment Reviews

View full text Add to dashboard Cite

“…This concept was evaluated for the first time in a randomized trial in 2003; which was updated in 2011. Briefly, Colombo et al [46] reported the outcomes of 65 patients with Ta-Ta and G1-3 BC who were randomized to receive intravesical chemohyperthermia (CHT) with MMC or intravesical MMC alone. All patients received 8 weekly, 60 min treatment sessions, followed by 4-monthly sessions.…”

Section: Device Assisted Therapies Chemothermotherapymentioning

confidence: 99%

Alternative therapies in patients with non-muscle invasive bladder cancer

Şanlı

Lotan

2017

Turkish Journal of Urology

View full text Add to dashboard Cite

Bladder cancer (BC) is one of the leading causes of cancer-related deaths worldwide. Despite, the majority of the cases were diagnosed as non-muscle invasive bladder cancer (NMIBC) with favorable prognosis, it has tendency to recur or progress to a higher grade or stage. The first line treatment of patients with NMIBC is transurethral resection with adjuvant therapies primarily intravesical Bacillus Calmette-Guérin (BCG) immunotherapy. However, in a portion of patients whose BCG treatment failed, alternative treatments may be required. Furthermore, intravesical BCG may be contraindicated in or untolerated by a group of patients. For these patients, some treatment options are readily available and a variety of them are currently under clinical investigation. In this review, these alternative therapies have been summarized.

show abstract

“…As mentioned earlier [66], the statistically significant superiority of RITE over BCG could possibly lead to a paradigm shift in the treatment of NMIBC, as no treatment was found comparable to the BCG gold standard for 40 years. Having discovered that RF is likely to have been the main protagonist of RITE over the years [57] (as it also induces the hyperthermia), it is interesting to point out that the effects of RF treatment are specific to cancer cells and are not limited to its hyperthermic property [59].…”

Section: Rf Applications In the Futurementioning

confidence: 99%

“…Another clinical paper [65] comparing the use of a heated MMC solution to the use of BCG, concluded that the Recurrence Free Survival (RFS) was significantly improved with the administration of BCG. In comparison, the recent paper on a multicentric, Randomized Controlled Trial of RITE vs. BCG in first line [66] showed a statistically significant superiority of RF+MMC over BCG in terms of RFS (81.8% vs. 64.8% in the PP, p=0.02). Though it has its limitations of an indirect comparison, it is clear that the mechanism employed in heating the drug, also in its clinical results, differs greatly from the effective RF mechanism.…”

Section: History Of Ritementioning

confidence: 99%

See 1 more Smart Citation

Intravesical Chemotherapy and Chemohyperthermia in Non-Muscle-Invasive Bladder Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics

Campodonico

Stasi

Lev³

et al. 2017

CDM

View full text Add to dashboard Cite

Background: Tumor recurrence is the most expected clinical event after the resection of non-muscle invasive bladder cancer, depending on histological findings of the initial lesion. In patients with low and intermediate risk of disease, the intravesical instillation of chemotherapy agents is recommended as a standard treatment to reduce recurrences. Methods:A comprehensive review covering various aspects of different treatments with intravesical drugs is presented.Results: Drugs may be instilled into the bladder starting with a single, 'early' postoperative administration or, after tumor resection with adjuvant intent or, before tumor resection under a neo-adjuvant regimen. Both latter protocols would consist of weekly treatments followed by monthly maintenance treatments. Different methods of administering drugs intravesically have been proposed to enhance the depth of drug penetration and its absorption into the bladder wall thus increasing the rate of drug-DNA reaction. These device-assisted therapies therefore have set a goal to potentiate the drug's effect and efficaciousness. The Radiofrequency-Induced Thermochemotherapeutic Effect (RITE) and the Electromotive-Drug Administration (EMDA) are the two most relevant modalities used to increase the activity of intravesical chemotherapy. Despite the widely adopted international guidelines' recommendations, and recent clinical trials of device-assisted chemotherapy instillations showing markedly enhanced recurrence-free survival compared even to the standard of care, clinicians and pharmacologists are not familiar with the in-depth physical aspects, pharmacokinetics and systemic absorption of chemotherapeutic drugs following their intravesical administration. Conclusion:Knowledge of drug diffusion mechanisms into the tissue and cellular cytoplasm following bladder instillation is a key to understand the safety profile and clinical activity of chemotherapy.

show abstract

Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non–Muscle-invasive Bladder Cancer

Cited by 204 publications

References 16 publications

Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia

Management of non-muscle invasive bladder cancer: A comprehensive analysis of guidelines from the United States, Europe and Asia

Alternative therapies in patients with non-muscle invasive bladder cancer

Intravesical Chemotherapy and Chemohyperthermia in Non-Muscle-Invasive Bladder Cancer; An Overview on Drug Administration Technologies and Pharmacokinetics

Contact Info

Product

Resources

About